AN2 Therapeutics reports Q1 2022 results, cash $118.4M; progresses epetraborole clinical program

AN2 Therapeutics, Inc.

Cash and investments total $118.4M as of March 31, 2022; expects operating runway through mid-2024.
Upsized IPO raised $79.4M; full exercise of underwriter option added $10.4M in April.
Phase 2/3 trial enrollment for treatment-refractory MAC lung disease expected to begin H1 2022.
FDA cleared IND, granted Fast Track, QIDP, and orphan drug designation for epetraborole.
Appointed Dr. Mel Spigelman and Maggie FitzPatrick to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.